Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10796323rdf:typepubmed:Citationlld:pubmed
pubmed-article:10796323lifeskim:mentionsumls-concept:C0012373lld:lifeskim
pubmed-article:10796323lifeskim:mentionsumls-concept:C0028066lld:lifeskim
pubmed-article:10796323lifeskim:mentionsumls-concept:C0028094lld:lifeskim
pubmed-article:10796323lifeskim:mentionsumls-concept:C0042523lld:lifeskim
pubmed-article:10796323lifeskim:mentionsumls-concept:C0543891lld:lifeskim
pubmed-article:10796323pubmed:issue2lld:pubmed
pubmed-article:10796323pubmed:dateCreated2000-7-6lld:pubmed
pubmed-article:10796323pubmed:abstractTextTardive dyskinesia (TD) is a potentially disfiguring movement disorder of the orofacial region often caused by use of neuroleptic drugs. A wide range of strategies have been used to help manage TD and, for those who are unable to have their antipsychotic medication stopped or substantially changed, the calcium-channel blocking group of drugs (diltiazem, nifedipine, nimodipine, verapamil) has been suggested as a useful adjunctive treatment.lld:pubmed
pubmed-article:10796323pubmed:languageenglld:pubmed
pubmed-article:10796323pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10796323pubmed:citationSubsetIMlld:pubmed
pubmed-article:10796323pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10796323pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10796323pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10796323pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10796323pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10796323pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10796323pubmed:statusMEDLINElld:pubmed
pubmed-article:10796323pubmed:issn1469-493Xlld:pubmed
pubmed-article:10796323pubmed:authorpubmed-author:McGrathJ JJJlld:pubmed
pubmed-article:10796323pubmed:authorpubmed-author:SoaresK VKVlld:pubmed
pubmed-article:10796323pubmed:issnTypeElectroniclld:pubmed
pubmed-article:10796323pubmed:ownerNLMlld:pubmed
pubmed-article:10796323pubmed:authorsCompleteYlld:pubmed
pubmed-article:10796323pubmed:paginationCD000206lld:pubmed
pubmed-article:10796323pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:meshHeadingpubmed-meshheading:10796323...lld:pubmed
pubmed-article:10796323pubmed:year2000lld:pubmed
pubmed-article:10796323pubmed:articleTitleDiltiazem, nifedipine, nimodipine or verapamil for neuroleptic-induced tardive dyskinesia.lld:pubmed
pubmed-article:10796323pubmed:affiliationDov Hoz Street, 27/16, Kfar Saba, Israel, 44356. ksoares@netvision.net.illld:pubmed
pubmed-article:10796323pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10796323pubmed:publicationTypeReviewlld:pubmed